The ne plus ultra for deep BCR-ABL sequencing?

Abstract

In this issue of Blood, Soverini et al demonstrate the benefits of ultra-deep sequencing (UDS) compared with conventional Sanger sequencing in detecting BCR-ABL kinase domain mutations. This might improve tailoring of the treatment for resistant patients with chronic myeloid leukemia and Ph + acute lymphoblastic leukemia (Ph+ ALL) in the future.